Healthcare Providers and Services
Company Overview of ARUP Laboratories, Inc.
ARUP Laboratories, Inc. operates a clinical and anatomic pathology reference laboratory in the United States. It offers ATOP, a laboratory analytics service to identify over-, under-, and mis-utilization of individual laboratory tests; ARUP Connect, an online information system for referral test management that enables to access test results, submit statistical data, and retrieve files; and ARUP Consult, a guide on PDA and Web platforms to assist the clinician with laboratory test selection and interpretation. The company also provides ARUP Direct, a start-to-finish outreach program to help clients; ARUP Gateway, an integrated customer test menu tool to serve the client's outreach medical co...
500 Chipeta Way
Salt Lake City, UT 84108-1221
Founded in 1984
Key Executives for ARUP Laboratories, Inc.
Chief Executive Officer and President
Chief Operating Officer and Executive Vice President of Corporate Communications
Senior Technical Vice President, Medical Director of Immunology & Infectious Disease Laboratory and Executive Director
Administrative Vice President and Medical Director of Animal Reference Pathology Laboratory
Senior Vice President and Director of Marketing
Compensation as of Fiscal Year 2015.
ARUP Laboratories, Inc. Key Developments
ARUP Laboratories and the Children's Hospital of Philadelphia Form Partnership to Offer High-Resolution HLA Genotyping by Next Generation Sequencing
Oct 8 14
ARUP Laboratories announced that they will be offering high-resolution HLA genotyping by next generation sequencing (NGS) under an agreement with The Children's Hospital of Philadelphia (CHOP). HLA genotyping is used for identifying the best recipient/donor match combination prior to hematopoietic stem cell transplantation (HSCT). HLA genes are the most polymorphic gene family found in the entire human genome, with more than 10,000 different HLA alleles reported so far. Currently, the standard of care for HLA genotyping to select a donor for HSCT is to use a low/intermediate resolution SSO/SSP test first and then reflex the candidates to confirmatory Sanger Sequence Based Typing (SBT) to obtain higher resolution allele information to finalize the matched donor. Sanger SBT produces incomplete and ambiguous results by analyzing only sections of the HLA genes and failing to distinguish among different alleles due to difficulty with resolving cis/trans chromosomal positions of those alleles. NGS is able to overcome the limitations of Sanger SBT by performing large number of long clonal sequencing reactions, allowing reporting of complete and unambiguous HLA genotyping results.
ARUP Laboratories Adds Prosigna to its Test Menu
Mar 5 14
ARUP Laboratories announced on March 3, that it has added the Prosigna Breast Cancer Prognostic Gene Signature assay to its comprehensive suite of breast cancer diagnostic tests. This assay is FDA 510(k) cleared for node-negative (stage I or II) or node-positive (stage II), hormone receptor-positive (HR+) breast cancer patients. Prosigna provides an individualized assessment of a patient's risk of recurrence at ten years given endocrine therapy alone. The test uses the biology of the tumor and clinical variables to assess risk and has shown improved prognostic accuracy over other breast cancer tests on the market. The University of Utah and the Huntsman Cancer Institute in Salt Lake City were integral in developing the 50-gene expression signature. Dr. Philip Bernard, a co-inventor of the test and medical director of molecular oncology diagnostics at ARUP Laboratories, oversees the test and can provide additional consultation through ARUP Client Services.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries